

Attorney/Docket No. 6643R2

Customer No. 027752

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Carnden, et al.

Serial No. 09/676,034

Filed: September 29, 2000

For: Compounds and Methods for Use
Thereof in the Treatment of
Cancer§
§
§
§
§
§
§
§
§
§
§

Group Art Unit: 1614

Examiner: C. Delacroix-Muirheid

RECEIVED
CENTRAL FAX CENTER

NOV 03 2003

OFFICIAL

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENTCommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with the duty of disclosure under 37 CFR §1.56, and in accordance with the practice under 37 CFR §1.97 and §1.98, the Examiner's attention is directed to the document listed on the enclosed modified Form PTO-1449. No inference should be made that the cited reference is in fact material, is in fact prior art, or that no better art exists. A copy of the listed information is attached.

This Information Disclosure Statement is being filed more than three months after the United States filing date and after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Action under §1.113 or Notice of Allowance under §1.311 (37 CFR §1.97(c)).

The Commissioner is hereby authorized to charge the fee under §1.17(p) (\$180) to Deposit Account 08-1394 for the filing of this Third Supplemental Information Disclosure Statement.

Attorney/Docket No. 6643R2
Customer No. 027752

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

Respectfully submitted,

Gloria L. Norberg

Gloria L. Norberg
Agent for Applicant
Registration No.: 36,706

Date: October 31, 2003
HAYNES AND BOONE, LLP
901 Main Street, Suite 3100
Dallas, Texas 75202-3789
Telephone: 512-867-8528
Facsimile: 512-867-8632

I hereby certify that this paper is being transmitted by facsimile to the Patent and Trademark Office on the date shown below.	
Fax Number: (703) 308-4242	
<u>Julie Schwartz</u>	
Julie Schwartz	
<u>Julie Schwartz</u>	
SIGNATURE	
<u>10/31/03</u>	
DATE OF TRANSMISSION	

In place of PTO-1449 Form		U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/676,034
				Filing Date	September 29, 2000
				Applicant(s)	Camden, et al.
				Art Unit	1614
				Examiner Name	C. Delacroix-Muirheid
SHEET 1 OF 1				Attorney Docket Number	6643R2

U. S. PATENT DOCUMENTS					
Ex- Init	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	

FOREIGN PATENT DOCUMENTS						
Ex- Init	Cite No.	Foreign Patent Document (Country Code - Number - Kind)	Publication Date MM-DD-YYYY	Patentee or Applicant of Cited Document	Translation Y/N	

OTHER PRIOR ART			
Ex- Init	Cite No.	Include name of the author (in CAPITAL LETTERS); title of the article; title of the journal; date; page(s); volume; issue number(s); publisher; city/country where published	
		CALABRESI and CHABNER, "Chemotherapy of Neoplastic Diseases", Goodman & Gilman's, The Pharmacological Basis of Therapeutics, Ninth Edition, (1996), pp. 1225-1229; The McGraw-Hill Companies.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--